Amylin – Talk Bio

Pfizer Acquires Metsera to Compete with Zepbound in Obesity Market

1 month ago talkbio0Tagged Acquisition, Amylin, Clinical Trials, dosing, Glucagon-Like Peptide 1, MET-097i, MET-233i, Metsera, mimetics, monthly, Obesity, Pfizer, Zepbound

Pfizer; Metsera; obesity treatment; Zepbound; GLP-1 therapies; MET-233i; monthly dosing; amylin mimetic; MET-097i; acquisition; clinical trials

Metsera Reports Once-Monthly Amylin Analogue Matches GLP-1 Efficacy in Early Phase 1 Results

5 months ago talkbio0Tagged Amylin, Clinical Trials, Glucagon-Like Peptide 1, MET-233i, Metsera, Obesity, once-monthly, Phase 1 (qualifier value), Weight-Loss

Metsera; MET-233i; amylin; obesity; weight-loss; GLP-1; once-monthly; clinical trial; phase 1

Versant Ventures Launches Pep2Tango Therapeutics with Revolutionary Tetra-Receptor Agonist Approach for Obesity Treatment

11 months ago talkbio0Tagged Amylin, Calcitonin Receptor, GIP/, GLP-1, muscle mass, Next, Next-generation weight loss therapies, Obesity, Pep2Tango, Peptides, Tetra-receptor, Ventures, Versant

Obesity treatment, Tetra-receptor agonist peptides, GLP-1/ GIP/ amylin/ and calcitonin receptors, Muscle mass preservation, Next-generation weight loss therapies, Versant Ventures, Pep2Tango Therapeutics Inc.

GUBamy, a Weekly Amylin Agonist, Shows Promising Weight Loss and Tolerability in Phase 1 Trial

12 months ago talkbio0Tagged Agonist, Amylin, GUBamy, long-acting, Obesity, phase 1 trial, Weight Loss

Amylin agonist, Obesity treatment, Weight loss, Phase 1 trial, GUBamy, Long-acting amylin agonist

Zealand Raises $1 Billion to Advance Amylin Obesity Drug and Seek Partnership

1 year ago talkbio0Tagged Amylin, Billion Raise, Obesity, Partnership, Weight Loss, Zealand Pharma

Zealand Pharma, Obesity, Amylin, Weight Loss, $1 Billion Raise, Partnership